+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Prostate Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
New

Prostate Cancer Diagnostics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337436
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Prostate Cancer Diagnostics Market is currently in a state of rapid evolution, shaped by changing clinical needs, new technologies, and the expectations of stakeholders across the healthcare ecosystem. Senior decision-makers require strategic insights and practical direction to navigate this landscape and maintain an effective competitive posture.

Market Snapshot: Prostate Cancer Diagnostics Market Growth and Outlook

The Prostate Cancer Diagnostics Market expanded from USD 1.63 billion in 2025 to USD 1.83 billion in 2026 and is expected to continue its upward trajectory, reaching USD 4.33 billion by 2032 at a CAGR of 14.97%. This sustained acceleration is attributed to breakthroughs in diagnostic methods, evolving care models, and an increased focus on early identification and precision risk management. Innovations in molecular diagnostics and imaging, combined with evolving reimbursement structures and a heightened push for earlier, more accurate diagnosis, are shaping the trajectory of this market for the foreseeable future. The underlying momentum is reinforced by emerging adoption patterns, stakeholder collaboration, and strategic investment in technology platforms tailored to meet diverse clinical needs.

Scope & Segmentation

This report offers a deep dive into market evolution, dissecting key segments, product categories, applications, and geographies pivotal for senior stakeholders. Market participants can align strategies with the following segmentation structure and leverage targeted opportunities across key domains.

  • Product Types: Biomarkers and kits (such as genetic, molecular diagnostics, and PSA testing), biopsy needles, and imaging platforms, including CT, MRI, PET, and ultrasound systems.
  • Test Types: Biopsy procedures, multiple imaging modalities, molecular assays (NGS and PCR), and PSA test methodologies.
  • End Users: Ambulatory surgical centers, diagnostic and pathology centers, hospital networks, outpatient clinics, and specialized research laboratories.
  • Technologies: Imaging solutions (including CT, MRI, PET, ultrasound), immunoassay formats (ELISA, RIA), and advanced molecular diagnostic techniques (NGS, PCR).
  • Applications: Use cases span genetic analysis, initial prostate cancer diagnosis, as well as ongoing monitoring and patient follow-up workflows.
  • Regions: Coverage includes the Americas, EMEA (Europe, Middle East & Africa), and Asia-Pacific. Each region demonstrates distinct adoption dynamics and market entry considerations, requiring tailored approaches to commercialization and partnership development.

Key Takeaways for Senior Leaders

  • Increased clinical demand is driving the development and adoption of solutions that deliver diagnostic accuracy and operational efficiency while minimizing total care costs.
  • The merging of molecular diagnostics, advanced imaging, and analytics is enabling earlier disease identification and optimized risk assessment, prompting organizations to reassess business and partnership models.
  • Strategic collaborations among molecular diagnostic providers, imaging system manufacturers, laboratory operators, and digital health companies are fostering integrated and value-driven diagnostic workflows.
  • Regional regulatory and payer structures introduce varied market requirements, highlighting the importance of region-specific strategies for evidence creation, reimbursement pathways, and local alliances.
  • Emerging innovators and specialized companies are leveraging novel technologies and biomarkers to disrupt legacy structures, intensifying competition and fueling acquisition interest and strategic partnerships.
  • Successful commercialization in this space requires robust clinical validation, scalable supply chain management, and the ability to adapt market access initiatives for sustained growth.

Tariff Impact on Procurement and Manufacturing

Recent tariff changes in the United States have reshaped procurement strategies and supply chain planning for the prostate cancer diagnostics industry. Increased tariffs on imported imaging equipment, diagnostic reagents, and kit components have prompted greater emphasis on supplier transparency among healthcare providers. Companies are evaluating nearshoring and local manufacturing to reduce exposure to trade risks, while procurement teams are reprioritizing resilience in sourcing and operational continuity. This shift underscores the necessity for adaptable supply strategies that respond proactively to evolving global trade dynamics and support uninterrupted clinical service.

Methodology & Data Sources

The research employs an integrated mixed-methods approach, combining structured interviews with clinicians, supply chain leaders, payers, and laboratory directors. In-depth technical reviews, regulatory analytics, and internal validation sessions ensure contextual accuracy and actionable recommendations tailored to industry stakeholders.

Why This Report Matters

  • Delivers actionable market intelligence that aligns clinical innovation, reimbursement planning, and operational decisions with a dynamic care delivery environment.
  • Provides segmentation clarity, allowing stakeholders to refine investment priorities and pursue high-potential areas with targeted go-to-market execution.
  • Offers risk mitigation insights, strengthening procurement and manufacturing planning against disruptive influences such as trade and supply chain challenges.

Conclusion

To achieve sustainable growth and reinforce competitive positioning in the prostate cancer diagnostics market, senior leaders need adaptive strategies rooted in innovation, structured evidence, and supply chain agility. This report empowers organizations to anticipate market shifts and realize opportunity across diverse industry segments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Prostate Cancer Diagnostics Market, by Product Type
8.1. Biomarkers & Kits
8.1.1. Genetic Testing Kits
8.1.2. Molecular Diagnostic Kits
8.1.3. Psa Tests
8.2. Biopsy Needles
8.3. Imaging Systems
8.3.1. Ct Systems
8.3.2. Mri Systems
8.3.3. Pet Systems
8.3.4. Ultrasound Systems
9. Prostate Cancer Diagnostics Market, by Test Type
9.1. Biopsy
9.2. Imaging Tests
9.2.1. Ct Tests
9.2.2. Mri Tests
9.2.3. Pet Tests
9.2.4. Ultrasound Tests
9.3. Molecular Tests
9.3.1. Ngs Tests
9.3.2. Pcr Tests
9.4. Psa Test
10. Prostate Cancer Diagnostics Market, by Technology
10.1. Imaging Modalities
10.1.1. Ct Modalities
10.1.2. Mri Modalities
10.1.3. Pet Modalities
10.1.4. Ultrasound Modalities
10.2. Immunoassays
10.2.1. Elisa
10.2.2. Ria
10.3. Molecular Diagnostics
10.3.1. Ngs Technologies
10.3.2. Pcr Technologies
11. Prostate Cancer Diagnostics Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Diagnostic Centers
11.3. Hospitals & Clinics
11.4. Research Laboratories
12. Prostate Cancer Diagnostics Market, by Application
12.1. Genetic Testing
12.2. Initial Diagnosis
12.3. Monitoring & Follow-Up
13. Prostate Cancer Diagnostics Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Prostate Cancer Diagnostics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Prostate Cancer Diagnostics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Prostate Cancer Diagnostics Market
17. China Prostate Cancer Diagnostics Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. bioMérieux SA
18.7. Danaher Corporation
18.8. Hologic, Inc.
18.9. Illumina, Inc.
18.10. Laboratory Corporation of America Holdings
18.11. MDxHealth SA
18.12. Myriad Genetics, Inc.
18.13. Proteomedix AG
18.14. QIAGEN N.V.
18.15. Quest Diagnostics, Inc.
18.16. Roche Diagnostics International AG
18.17. Siemens Healthineers AG
18.18. Thermo Fisher Scientific Inc.
18.19. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 183. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 184. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 185. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 186. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 188. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 189. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 190. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 191. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 192. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 207. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 209. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 210. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 211. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 212. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 213. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 214. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 215. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 216. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 217. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 218. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 233. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 234. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 236. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 237. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 238. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 239. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 240. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 241. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 242. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 243. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 244. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 245. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 247. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 249. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 250. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 251. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 252. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 253. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 254. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 255. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 256. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 257. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 258. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 273. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 274. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 275. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 276. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 277. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 278. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 279. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 280. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 281. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 282. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 283. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 284. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 285. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 286. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 287. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 288. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 289. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 290. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 291. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 292. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 293. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 294. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2032 (USD MILLION)
TABLE 295. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
TABLE 296. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 297. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 298. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 299. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 300. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 301. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
TABLE 302. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
TABLE 303. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 304. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
TABLE 305. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 306. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION

Companies Mentioned

The key companies profiled in this Prostate Cancer Diagnostics market report include:
  • Abbott Laboratories
  • bioMérieux SA
  • Danaher Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • Proteomedix AG
  • QIAGEN N.V.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics International AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.83 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.33 Billion
Compound Annual Growth Rate14.9%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From
AI in Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

AI in Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Prostate Cancer Diagnostics - Global Strategic Business Report - Product Image

Prostate Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Prostate Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Prostate Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 140 Pages
  • Global
From

About the Prostate Cancer Diagnostics Market

The Prostate Cancer Diagnostics market is a segment of the Diagnostics industry that focuses on the detection and diagnosis of prostate cancer. Diagnostic tests for prostate cancer include digital rectal exams, prostate-specific antigen (PSA) tests, and biopsies. These tests are used to detect the presence of cancer, as well as to monitor the progression of the disease. In recent years, advances in technology have enabled the development of more accurate and reliable diagnostic tests for prostate cancer. These tests have improved the accuracy of diagnosis and have enabled earlier detection of the disease. Additionally, the development of new treatments for prostate cancer has increased the demand for diagnostic tests. The Prostate Cancer Diagnostics market is highly competitive, with a number of companies offering a range of diagnostic tests. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.